HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $5 price target.
Outlook Therapeutics Q1 EPS $(0.08) Misses $(0.04) Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.04) by 100 percent. This is a 14.29 percent decrease over losses of $(0.07) per share
HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Lowers Price Target to $5
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and lowers the price target from $6 to $5.
What’s Next For Stocks After S&P 500 Wraps Roughest Year Since 2008?
The SPDR S&P 500 ETF Trust (NYSE: SPY) 500 declined for the fourth consecutive week as the stock market completed its worst year in more than a decade.
Earnings Scheduled For December 27, 2022
Companies Reporting Before The Bell
• Outlook Therapeutics (NASDAQ:OTLK) is expected to report earnings for its fourth quarter.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Earnings Outlook For Outlook Therapeutics
Outlook Therapeutics (NASDAQ:OTLK) is set to give its latest quarterly earnings report on Tuesday, 2022-12-27. Here’s what investors…
Can The Economy Weather Inflation, A Winter Storm, Elon Musk?
The S&P 500 traded lower for the third consecutive week on concerns inflation may be more stubborn than anticipated.
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Autolus Therapeutics (NASDAQ:AUTL) stock moved upwards by 15.0% to $2.3 during Tuesday’s after-market session. The market value…
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Benitec Biopharma (NASDAQ:BNTC) shares increased by 9.8% to $0.35 during Tuesday's after-market session. The company's market cap stands at $9.0 million.